SequelSEC

Atea Pharmaceuticals, Inc. AVIR

Pharmaceutical Preparations · CIK 0001593899 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
$192.18M
Fiscal year ended 2021-12-31
Operating income
$121.18M
Fiscal year ended 2021-12-31
Free cash flow
Unavailable
Fiscal year ended 2021-12-31

Valuation, from the filing

Public float$262.60MMarket value of stock held by non-affiliates, as stated on the cover page for 2025-06-30
Float per share$3.30Float divided by shares outstanding in the same filing. A floor under the share price on that date, not the price itself.

Every figure here is drawn from the 10-K cover page and the statements behind it, so each one traces to a filing. Public float counts only stock held by non-affiliates, which makes these floors rather than estimates: a high multiple is conclusive, a low one may mean cheap or may mean closely held. The float was measured on 2025-06-30, not today.

How this compares in its industry

Percentile among the Pharmaceutical Preparations filers on this site, highest value first. A high percentile means a large figure, which is good for a margin and not for leverage — the ranking says where the company sits, not whether that is where it should be.

MeasureReportedPercentile
Operating margin39.4%97th
CapEx / revenue0.0%4th
Revenue YoY growth622.5%94th
Net margin34.5%93th
Current ratio13.58x88th
R&D / revenue47.6%34th
SBC / revenue11.3%38th
Effective tax rate12.6%39th
FCF margin-24.8%60th

Atea Pharmaceuticals, Inc. (AVIR) reported revenue of $192.18M and net income of $117.13M for the fiscal year ended 2021-12-31. This page shows 5 annual periods of income statement, balance sheet and cash flow figures normalized from Atea Pharmaceuticals, Inc.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Pharmaceutical Preparations.

Income

Atea Pharmaceuticals, Inc. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2021-12-312021-09-302021-06-302021-03-312020-12-31
Revenue$192.18M$32.81M$60.39M$65.98MUnavailable
Cost of revenueUnavailableUnavailableUnavailableUnavailableUnavailable
Gross profitUnavailableUnavailableUnavailableUnavailableUnavailable
Operating income$121.18M-$22.15M$8.69M$30.66MUnavailable
Net income$117.13M-$28.19M$1.54M$30.71MUnavailable
Research & development$57.81M$43.02M$39.80M$26.57MUnavailable
Weighted-average diluted sharesUnavailableshares 82.82Mshares 88.09Mshares 89.10MUnavailable
Pretax income$121.23M-$22.09M$8.74M$30.71MUnavailable
Income tax expense$4.10M$6.10M$7.20MUnavailableUnavailable
Diluted EPSUnavailable$-0.34$0.02$0.34Unavailable
Selling, general & administrativeUnavailableUnavailableUnavailableUnavailableUnavailable
General & administrative$13.19M$11.94M$11.90M$8.76MUnavailable
Selling & marketingUnavailableUnavailableUnavailableUnavailableUnavailable

Balance

Atea Pharmaceuticals, Inc. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2021-12-312021-09-302021-06-302021-03-312020-12-31
Cash & equivalents$764.38M$839.66M$816.46M$833.75M$850.12M
Total assets$772.89M$843.50M$871.54M$840.65M$863.63M
Current assets$772.40M$842.95M$871.11M$840.14M$863.48M
Total liabilities$62.82M$262.05M$273.68M$254.39M$315.83M
Current liabilities$56.88M$262.05M$273.65M$254.28M$315.80M
Total equity incl. NCI$710.08M$581.45M$597.86M$586.26M$547.80M
Temporary (mezzanine) equityUnavailableUnavailableUnavailableUnavailableUnavailable
InventoryUnavailableUnavailableUnavailableUnavailableUnavailable
Accounts receivableUnavailableUnavailable$50.00MUnavailableUnavailable
GoodwillUnavailableUnavailableUnavailableUnavailableUnavailable
Long-term debtUnavailableUnavailableUnavailableUnavailableUnavailable
Accounts payable$4.53M$22.19M$10.70M$3.79M$60.00K

Cash flow

Atea Pharmaceuticals, Inc. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2021-12-312021-09-302021-06-302021-03-312020-12-31
Operating cash flow-$75.42M$22.60M-$17.35M-$16.84MUnavailable
Capital expendituresUnavailableUnavailableUnavailableUnavailableUnavailable
Investing cash flowUnavailableUnavailableUnavailableUnavailableUnavailable
Financing cash flow$142.00K$795.00K$57.00K$471.00KUnavailable
Net change in cash-$75.28M$23.40M-$17.29M-$16.37MUnavailable
Stock-based compensation$11.35M$10.99M$10.01M$7.27MUnavailable
Common dividends paidUnavailableUnavailableUnavailableUnavailableUnavailable
Common share repurchasesUnavailableUnavailableUnavailableUnavailableUnavailable
Depreciation & amortization$7.00K$7.00K$8.00K$7.00KUnavailable

Derived

Atea Pharmaceuticals, Inc. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2021-12-312021-09-302021-06-302021-03-312020-12-31
Free cash flowUnavailableUnavailableUnavailableUnavailableUnavailable
Gross marginUnavailableUnavailableUnavailableUnavailableUnavailable
Operating margin63.1%-67.5%14.4%46.5%Unavailable
FCF marginUnavailableUnavailableUnavailableUnavailableUnavailable
SBC / revenue5.9%33.5%16.6%11.0%Unavailable
Current ratio13.58x3.22x3.18x3.30x2.73x
Revenue YoY growthUnavailableUnavailableUnavailableUnavailableUnavailable
Net margin60.9%-85.9%UnavailableUnavailableUnavailable
R&D / revenue30.1%131.1%65.9%40.3%Unavailable
CapEx / revenueUnavailableUnavailableUnavailableUnavailableUnavailable
Long-term debt / equityUnavailableUnavailableUnavailableUnavailableUnavailable
Effective tax rate3.4%Unavailable82.4%UnavailableUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open AVIR in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-12View SEC filing
10-Q · Filed 2026-05-12View SEC filing
10-K · Filed 2026-03-05View SEC filing
10-Q · Filed 2025-11-12View SEC filing
10-Q · Filed 2025-08-07View SEC filing
10-Q · Filed 2025-05-12View SEC filing

Companies in the same industry

AAGH AARD ABBV ABCL ABEO ABT ABUS ABVC ACAD ACET ACRS ACRV

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.